What does LAUNXP Biomedical Co., Ltd do?

LAUNXP Biomedical Co., Ltd (6876.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6876.TWO's market cap?

LAUNXP Biomedical Co., Ltd (6876.TWO) has a market capitalization of approximately $834.1 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6876.TWO pay a dividend?

No — LAUNXP Biomedical Co., Ltd (6876.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6876.TWO profitable?

LAUNXP Biomedical Co., Ltd (6876.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6876.TWO

LAUNXP Biomedical Co., Ltd

TWO·Biotechnology · Healthcare

NT$12.05NT$0.05+0.42%

Market capNT$834.07M·Aug 26 6:59 AM UTC

Price Chart

NT$12.05+NT$0.05 (+0.42%)today

−46.21%CAGR −21.19%

Select date range

FromTo

Jan 18, 2024Jan 18, 2024 → Aug 26, 2026· 2.6 yrsAug 26, 2026

Key Metrics

6876.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$720.00K

Net Income−NT$449.49M

Net Margin−62,429.4%

Operating Cash Flow−NT$127.98M

Capital ExpendituresNT$1.86M

Free Cash Flow−NT$129.84M

Return on Equity−121.8%

Return on Invested Capital−19.6%

Net CashNT$448.41M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6876.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6876.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6876.TWO and 80,000+ other tickers.

About LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical treatments for various types of cancer. Their product line includes therapies designed to combat tumor growth and inhibit cell proliferation, notably utilizing advanced platforms such as virus-like nanoparticles and other nanoparticle-based drug delivery systems. The company was established on September 24, 2015, and its primary corporate operations are based in Taichung, Taiwan.

CEO: Chiu-Heng Chen
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 35
Website: www.launxp.com

Peers

Peers Tab

7725.TWO

LabTurbo Biotech Corporation

Cap

NT$1.1B

6810.TWO

Bio Preventive Medicine Corp.

Cap

NT$1.1B

6814.TWO

Lukas Biomedical Inc.

Cap

NT$833.3M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6876.TWO

What does LAUNXP Biomedical Co., Ltd do?: LAUNXP Biomedical Co., Ltd (6876.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6876.TWO's market cap?: LAUNXP Biomedical Co., Ltd (6876.TWO) has a market capitalization of approximately $834.1 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6876.TWO pay a dividend?: No — LAUNXP Biomedical Co., Ltd (6876.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6876.TWO profitable?: LAUNXP Biomedical Co., Ltd (6876.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.